GPT and blood coagulation disease: To further investigate the clinical significance of the markedly higher levels of circulating cell death biomarkers in HBV-ACLF patients, we performed regression analyses to compare levels of cell death biomarkers with well-established liver injury markers including ALT and AST, with HBV-DNA load and additionally with albumin, TB and INR, since decreased albumin, hyperbilirubinemia and coagulopathy are the hallmarks of liver manifestation of ACLF patients.